BET family protein degraders poised to join the senolytic arsenal

por Guo, Zufeng, Peng, Hanjing, Xie, Yongmei
Publicado 2020

Corrigendum: Prostaglandin reductase 1 as a potential therapeutic target for cancer therapy

por Wang, Xing, Yin, Guobing, Zhang, Wei, Song, Kunling, Zhang, Longbin, Guo, Zufeng
Publicado 2023

Prostaglandin Reductase 1 as a Potential Therapeutic Target for Cancer Therapy

por Wang, Xing, Yin, Guobing, Zhang, Wei, Song, Kunling, Zhang, Longbin, Guo, Zufeng
Publicado 2021

Signaling Pathway and Small-Molecule Drug Discovery of FGFR: A Comprehensive Review

por Zheng, Jia, Zhang, Wei, Li, Linfeng, He, Yi, Wei, Yue, Dang, Yongjun, Nie, Shenyou, Guo, Zufeng
Publicado 2022

Influence of stereochemistry on the activity of rapadocin, an isoform-specific inhibitor of the nucleoside transporter ENT1

por Wang, Yuefan, Peng, Hanjing, Guo, Zufeng, Ullman, Brett R., Yamamoto, Kana, Hong, Sam Y., Liu, Jun O.
Publicado 2021

Rapamycin-inspired macrocycles with new target specificity

por Guo, Zufeng, Hong, Sam Y., Wang, Jingxin, Rehan, Shahid, Liu, Wukun, Peng, Hanjing, Das, Manisha, Li, Wei, Bhat, Shridhar, Peiffer, Brandon, Ullman, Brett R., Tse, Chung-Ming, Tarmakova, Zlatina, Schiene-Fischer, Cordelia, Fischer, Gunter, Coe, Imogen, Paavilainen, Ville O., Sun, Zhaoli, Liu, Jun O.
Publicado 2018